Outcomes of renal transplants from centers for disease control and prevention high-risk donors with prospective recipient viral testing: A single-center experience

Archives of Surgery

Volumn 146, Issue 11, 2011, Pages 1261-1266

  Lonze, Bonnie E ^a   Dagher, Nabil N ^a   Liu, Minghao ^a   Kucirka, Lauren M ^a   Simpkins, Christopher E ^a   Locke, Jayme E ^a   Desai, Niraj M ^a   Cameron, Andrew M ^a   Montgomery, Robert A ^a   Segev, Dorry L ^a   Singer, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ADULT; ARTICLE; DISEASE CONTROL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; VIRUS DIAGNOSIS; VIRUS TRANSMISSION;

ADULT; BALTIMORE; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS; UNITED STATES; VIRUS DISEASES; WAITING LISTS;

EID: 81855211076     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.267     Document Type: Article

References (20)

1. OPTN/SRTR Annual Report: Transplant Data 1998-2007. 2008. http://optn.transplant.hrsa.gov/ar2008/.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725- 1730.
3. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9(11):2135-2141. (Pubitemid 28482164)
4. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA. 2005;294(21):2726-2733. (Pubitemid 41770102)
5. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3(suppl 4):114-125. (Pubitemid 36612389)
6. Gagandeep S, Matsuoka L, Mateo R, et al. Expanding the donor kidney pool: utility of renal allografts procured in a setting of uncontrolled cardiac death. Am J Transplant. 2006;6(7):1682-1688. (Pubitemid 43945810)
7. Kucirka L, Dagher N, Montgomery R, Segev D, Singer A. High infectious risk organ donors in kidney transplantation: risks, benefits, and current practices. Dial Transplant. 2010;39(5):186-189.
8. Kucirka LM, Ros RL, Subramanian AK, Montgomery RA, Segev DL. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation. Arch Surg. 2011;146(1):41-45.
9. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1176-1187.
10. Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant. 2009;9(3):620-628.
11. Kucirka LM, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Formal policies and special informed consent are associated with higher provider utilization of CDC high-risk donor organs. Am J Transplant. 2009;9(3):629-635.
12. Kucirka LM, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys. Am J Transplant. 2009;9(5):1197-1204.
13. Centers for Disease Control and Prevention. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Recomm Rep. 1994;43(RR-8):1-17.
14. United Network for Organ Sharing Identification of transmissible diseases in organ recipients. 2008. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/ policies/pdfs/policy-16.pdf. Accessed August 5, 2011.
15. Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramanian AK, Segev DL. The high-risk donor: viral infections in solid organ transplantation. Curr Opin Organ Transplant. 2008;13(4):400-404.
16. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet. 2004;364(9445):1611-1612. (Pubitemid 39446386)
17. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.
18. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the "best" test the right test? a consensus conference report. Am J Transplant. 2010;10(4):889-899.
19. Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant. 2007;7(6):1515-1525. (Pubitemid 46776240)
20. Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant. 2009;9(1):23-30.